CAR-T cell therapy plus stem cell transplant for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia must have come back or not responded to standard treatments.
- Your leukemia cells must have at least 80% of a marker called CD123 or CLL-1 (a special protein on the cancer cells).
- You are between 18 and 75 years old.
- Your heart, lungs, kidneys, and liver are working well enough.
- You can do your daily activities without help (Karnofsky score of 80 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
Hear when a new AML - Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.